International Journal of Pharmacology and Clinical Research

ISSN Print: 2664-7613
ISSN Online: 2664-7621
Impact Factor: (RJIF) 8.29
IJPCR 2025; 7(2): 304-307
www.pharmacologyjournal.in
Received: 16-07-2025
Accepted: 18-08-2025

Dr. Azra Anjum
Doctor of Pharmacy, Sree Dattha Institute of Pharmacy Seriguda, Hyderabad, Telangana, India

Dr. G Sudhakara Rao
HOD, Department of Pharmacology, MRM College of Pharmacy, Hyderabad, Telangana, India

Dr. Mujtaba Ahmed
Professor and HOD, Department of Pharmaceutical Chemistry, MRM College of Pharmacy, Chintapllyguda, Hyderabad, Telangana, India

Vinjavarapu L Anusha
Associate Professor, SIMS College of Pharmacy, Mangaldas Nagar, Guntur, Andhra Pradesh, India

Muskan
Doctor of Pharmacy, MRM College of Pharmacy, Chintapllyguda, Hyderabad, Telangana, India

Mohammed Khadeer
Doctor of Pharmacy, MRM College of Pharmacy, Chintapllyguda, Hyderabad, Telangana, India

Rizwana Afreen
Doctor of Pharmacy, MRM College of Pharmacy, Chintapllyguda, Hyderabad, Telangana, India

Nabila Moiz
Doctor of Pharmacy, MRM College of Pharmacy, Chintapllyguda, Hyderabad, Telangana, India

Nadia Fatima
Doctor of Pharmacy, MRM College of Pharmacy, Chintapllyguda, Hyderabad, Telangana, India

Mahvish Naaz
Doctor of Pharmacy, MRM College of Pharmacy, Chintapllyguda, Hyderabad, Telangana, India

Saniya Sultana
Doctor of Pharmacy, MRM College of Pharmacy, Chintapllyguda, Hyderabad, Telangana, India

Corresponding Author:
Dr. Azra Anjum
Doctor of Pharmacy, Sree Dattha Institute of Pharmacy Seriguda, Hyderabad, Telangana, India

A review on advances in pharmacological treatment of CNS and ANS disorders

Azra Anjum, G Sudhakara Rao, Mujtaba Ahmed, Vinjavarapu L Anusha, Muskan, Mohammed Khadeer, Rizwana Afreen, Nabila Moiz, Nadia Fatima, Mahvish Naaz and Saniya Sultana

DOI: https://doi.org/10.33545/26647613.2025.v7.i2d.123

Abstract
The central nervous system (CNS) and autonomic nervous system (ANS) are pivotal in regulating the body's homeostasis, cognition, and adaptive responses. Recent advances in neuroscience, molecular biology, and neuroimaging have significantly enhanced our understanding of the physiological functions and interconnectivity of these systems. This review explores cutting-edge discoveries in CNS network dynamics, neuroplasticity, neuroimmune interactions, and brain-gut-microbiome communication. Simultaneously, the autonomic system has seen transformative developments in mapping sympathetic-parasympathetic functions, bioelectronic modulation, and its role in immunoregulation and metabolic control. Emerging technologies such as single-cell transcriptomics, optogenetics, and non-invasive neuromodulation are reshaping clinical and research paradigms. This paper highlights the translational impact of these findings on neurodegenerative diseases, psychiatric disorders, cardiovascular dysfunctions, and inflammatory conditions. The review provides a comprehensive update for clinicians, neuroscientists, and biomedical researchers aiming to integrate physiological understanding with therapeutic innovation.

Keywords: central nervous system (CNS), autonomic nervous system (ANS), neurophysiology, neuroplasticity, neuroimmune interactions, vagus nerve stimulation, brain-gut axis, bioelectronic medicine, neuroinflammation, glymphatic system, neurocardiology and translational neuroscience, cns pharmacology, alzheimer's disease, parkinson's, beta-3 agonists, autonomic neuropathy

Introduction
Treatment for Central Nervous System (CNS) and Autonomic Nervous System (ANS) disorders described as, varies widely by condition and includes medication, surgery, therapy (including counseling and neural rehabilitation), and supportive care. Specific examples mentioned include beta-blockers and botulinum toxin for autonomic issues, antidotes like flumazenil for CNS depression, and interventions such as clean intermittent catheterization for neurogenic bladder.

General Treatment Approaches
1. **Medications:** This can include antihypertensive drugs, anticholinergics, antidotes for drug overdose, and beta-blockers.
2. **Surgery:** Surgical interventions are used in some cases, with examples including urinary diversion for bladder issues and various neuromodulation techniques [1-2].
3. **Therapy and Rehabilitation:** This can encompass neural rehabilitation, biofeedback training, counseling for mental support, and physical therapies.
4. **Behavioral Modifications:** These can include changes to water intake or exercises like Kegel exercises for conditions like neurogenic bladder.
5. **Supportive Care:** Measures are taken to maintain comfort and manage symptoms like dysphagia (difficulty swallowing).
6. **Central nervous system depression:** Agents like naloxone and flumazenil are used to reverse the effects of sedatives.
7. **Infections:** Treatment depends on the specific microorganism (bacterial, viral, parasitic, or fungal) that is causing the infection [3-5].

Specific Examples of ANS Treatments

1. **Autonomic dysreflexia:** Antihypertensive medications (e.g., nitrates, hydralazine) and ganglionic blockers are used, as are topical analgesics like lidocaine. Botulinum toxin may also be used to treat bladder dysfunction triggering attacks.
2. **Neurogenic bladder:** This can be managed with behavioral changes, clean intermittent catheterization, pharmacological treatments (anticholinergic drugs, bethanechol), Botox injections, and surgical options.
3. **Paroxysmal sympathetic hyperactivity (PSH):** Beta-blockers, such as propranolol, are effective in reducing symptoms.

Neurological disorders represent a complex array of medical conditions that fundamentally disrupt the functioning of the nervous system. These disorders affect the brain, spinal cord, and nerve networks, presenting unique diagnosis, treatment, and patient care challenges. At their core, they represent disruptions to the intricate communication systems within the nervous system, stemming from genetic predispositions, environmental factors, infections, structural abnormalities, or degenerative processes [6-7].

The impact of neurological disorders is profound and far-reaching. Conditions like epilepsy create recurring seizures through abnormal electrical brain activity, while multiple sclerosis damages the protective myelin covering of nerve fibers, interrupting communication between the brain and body. Parkinson's disease progressively affects movement through the loss of dopamine-producing nerve cells, and strokes can cause immediate and potentially permanent neurological damage by interrupting blood flow to the brain. Neuroimaging technologies like MRI and CT scans and electroencephalograms provide crucial insights into the intricate changes occurring within the nervous system. Treatment approaches are equally complex, involving multidisciplinary strategies, including medications to manage symptoms, control brain activity, or slow disease progression, coupled with neurological rehabilitation to help patients develop compensatory strategies [8].

Central Nervous System (CNS)

I. Brain Connectomics and Network Physiology

1. High-resolution mapping (via fMRI, diffusion tensor imaging, and connectomics) has revealed that:

- The brain operates via dynamic, modular networks rather than isolated regions.
- Real-time shifts in network integration and segregation explain how attention, memory, and consciousness emerge.

2. Human Connectome Project (HCP) data is aiding the development of AI models for predicting brain-behavior relationships.

II. Neuroplasticity and Adult Neurogenesis

Advances in *in vivo* imaging and transcriptomics have shown

- The hippocampus continues neurogenesis in adulthood, modulated by exercise, sleep, and inflammation.
- Rewiring through synaptic pruning and dendritic remodeling is more extensive than previously thought, even in aging brains.

III. Glial Cells & Neuroimmune Interactions

Glias are now seen as active regulators of CNS physiology, not just support cells:

- Astrocytes regulate synaptic strength, blood flow, and sleep via gliotransmission.
- Microglias play a role in synaptic pruning, neuroinflammation, and neurodevelopment disorders (e.g., autism, schizophrenia).
- Discovery of the glymphatic system (glial-lymphatic pathway) has reshaped our understanding of brain waste clearance, especially during sleep.

IV. CNS lymphatics & immune surveillance

Discovery of meningeal lymphatic vessels has shown the CNS is not completely immune-privileged. These vessels facilitate immune cell trafficking and waste clearance, with implications in neurodegenerative diseases like Alzheimer's [9].

V. Brain-Gut-Microbiome Axis

The gut microbiome significantly affects CNS function via:

- Vagal nerve signaling, microbial metabolites (e.g., SCFAs), and cytokines.
- Shown to impact mood, cognition, and neurodevelopment.
- Microbiota modulation is being explored in depression, anxiety, Parkinson's, and multiple sclerosis.

VI. Cognitive Enhancement via Neuromodulation

- Emerging technologies like transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), and focused ultrasound are: Modulating cortical excitability and improving cognitive recovery in stroke, TBI, and depression.

Autonomic Nervous System (ANS)

1. ANS Mapping and Bioelectronic Medicine

- Single-cell RNA sequencing and optogenetics are refining our understanding of sympathetic vs. parasympathetic fibers.
- Development of bioelectronic therapies to modulate ANS function:
  - Vagus nerve stimulation (VNS) for epilepsy, depression, and inflammatory diseases.
  - Closed-loop neural interfaces for autonomic control in cardiac, gastrointestinal, and immune disorders[10].

2. ANS and Inflammatory Reflex

The cholinergic anti-inflammatory pathway is central in:

- Suppressing systemic inflammation and cytokine storms.
- Being tested in sepsis, COVID-19, rheumatoid arthritis, and Crohn's disease.

3. Autonomic Control of Metabolism

ANS regulation of glucose, lipid metabolism, and energy expenditure is being revisited:

- Sympathetic nerves to adipose tissue mediate fat browning and thermogenesis.
- Vagal pathways modulate insulin sensitivity and gut hormone secretion (GLP-1, PYY).

4. Neurocardiology and Heart-Brain Axis

- **Growing evidence of bidirectional communication:**

- Sympathetic overactivity contributes to heart failure, arrhythmias.
- Heart rate variability (HRV) is a robust biomarker of ANS balance and cognitive/emotional health.
- Cardiac afferents influence stress, emotion, and memory encoding.

5. Central Autonomic Network (CAN)

Composed of insula, amygdala, hypothalamus, and brainstem nuclei.

- Modern imaging has highlighted neurovisceral integration, linking CAN to anxiety, depression, IBS, and PTSD.
- Alterations in functional connectivity of CAN see in hypertension and autonomic failure.

Emerging Tools & Technologies

Technology	Application
1. Single cell transcriptomics:	CNS and ANS cell types and functions
2. CLARITY, iDISCO:	3D tissue clearing for visualizing nerve networks
3. CRISPR/Cas gene editing:	Targeting specific neuron populations for function studies
4. Real-time fMRI neurofeedback:	Training voluntary control of CNS/ANS functions
5. Artificial intellegence/ Machine learning for neurophysiological data:	Pattern recognition in EEG, ECG, autonomic profiles
6. Wearable biosensors:	Tracking HRV, skin conductance, and other ANS indicators

Translational & Clinical Implications

Alzheimer's Disease: Glymphatic dysfunction, neuroinflammation, microbiome shifts

Hypertension: Sympathetic overactivity; central autonomic dysfunction

Anxiety/Depression: Dysregulation of CAN; vagus-mediated anti-inflammatory tone

Diabetes: ANS dysfunction in early detection; vagal modulation of glucose

Multiple Sclerosis: Gut-brain axis, microglial activation, autonomic dysfunction

Long COVID: Persistent ANS dysautonomia, neuroinflammation, vagal dysfunction [11].

Advances in the Pharmacological Treatment of CNS and ANS Disorders

1. Central Nervous System (CNS) Disorders

a. Neurodegenerative Diseases

- **Alzheimer's Disease (AD)**

a. Lecanemab (Leqembi): Recently approved by the FDA (2023), it's a monoclonal antibody targeting amyloid-beta, showing slowed cognitive decline in early AD.

b. Donanemab: Another anti-amyloid agent under Phase 3 trials showing promise in early-stage AD.

c. Neuroinflammation modulators: Drugs targeting glial cells (e.g., P2X7 receptor antagonists) are in development for reducing inflammation-driven neuronal damage.

- **Parkinson's Disease (PD)**
- **Opicapone:** A once-daily COMT inhibitor for motor fluctuation control.
- **Gene therapy and cell transplantation:** Clinical trials using AAV vectors and stem-cell-derived dopaminergic neurons show potential for long-term disease modification.

b. Psychiatric Disorders

Major Depressive Disorder (MDD)

- **Esketamine nasal spray:** A fast-acting NMDA receptor antagonist approved for treatment-resistant depression.
- **Psychedelic-assisted therapy:** Agents like psilocybin and MDMA are being investigated in controlled settings for MDD and PTSD.
- **Schizophrenia**
- **SEP-363856:** A novel psychotropic agent that acts independently of D2 dopamine receptor antagonism.
- **Long-acting injectables (LAIs):** Improving adherence and reducing relapse rates.

c. Epilepsy

- **Cenobamate:** A new anti-seizure medication with dual mechanisms (sodium channel inhibition + GABA-A modulation) showing efficacy in drug-resistant epilepsy.
- **Targeted therapies:** mTOR inhibitors (e.g., everolimus) are being used in tuberous sclerosis complex-related seizures [12].

2. Autonomic Nervous System (ANS) Disorders

a. Autonomic Neuropathies

- **Immunotherapies (e.g., IVIG, corticosteroids):** Used in autoimmune autonomic ganglionopathy.
- **Midodrine and droxidopa:** FDA-approved drugs for treating neurogenic orthostatic hypotension**,** acting via vasoconstriction and norepinephrine pathways respectively.

b. Overactive Bladder and Urinary Disorders

- **Beta-3 adrenergic agonists (e.g., mirabegron):** Improve bladder capacity and reduce urgency without anticholinergic side effects.
- **Vibegron:** A newer beta-3 agonist with fewer cardiac side effects compared to mirabegron.

c. Cardiovascular Dysautonomia

- **Ivabradine:** A selective, if channel inhibitor used off-label for inappropriate sinus tachycardia in postural orthostatic tachycardia syndrome (POTS).
- **Ranolazine:** Emerging use in treating POTS-related chest pain and fatigue.

3. Emerging Technologies and Drug Delivery

- **Blood-brain barrier (BBB) targeting nanocarriers:** Allow selective drug delivery to CNS tissue (e.g., liposomal or exosome-based delivery).

- **Gene-editing therapies (CRISPR/Cas9):** Under research for monogenic CNS diseases like Huntington's disease.
- **mRNA-based therapies:** Post-COVID platform developments have led to experimental CNS applications [13].

Conclusion

This study is aimed to control and reduce the severity of various diseases of CNS and ANS in humanbeings.The advanced studies helpful to protect the lives and estimate the disease conditions and further reducing the mortality rate of human beings.

References

1. Thakur KT, Albanese E, Giannakopoulos P, Jette N, Linde M, Prince MJ, *et al*. Neurological disorders. In: Patel V, Chisholm D, Dua T, *et al*., editors. Mental, Neurological, and Substance Use Disorders: Disease Control Priorities, Third Edition. Vol. 4. Washington (DC): World Bank; c2016, p. 87-107.
2. Zis P, Hadjivassiliou M. Treatment of neurological manifestations of gluten sensitivity and coeliac disease. Curr Treat Options Neurol. 2019;21(3):10.
3. World Health Organization. Neurological disorders: public health challenges [Internet]. Geneva: WHO; 2007 Mar 14 [cited 2025 Oct 11]. Available from: https://www.who.int/publications/i/item/neurological-disorders-public-health-challenges
4. Sanders T, Liu Y, Buchner V, Tchounwou PB. Neurotoxic effects and biomarkers of lead exposure: a review. Rev Environ Health. 2009;24(1):15-45.
5. National Institute for Health and Care Excellence (NICE). Coeliac disease: recognition, assessment and management. NICE guideline [NG20] [Internet]. London: NICE; 2015 Sep [cited 2025 Oct 11]. Available from: https://www.nice.org.uk/guidance/ng20
6. Li Y, Peppelenbosch MP. Hepatitis E virus and neurological manifestations. J Neurol Sci. 2020;423:117388.
7. Abugable AA, Morris JLM, Palminha NM, Zaksauskaite R, Ray S, El-Khamisy SF. DNA repair and neurological disease: from molecular understanding to the development of diagnostics and model organisms. DNA Repair (Amst). 2019;81:102669.
8. U.S. National Library of Medicine. Central nervous system diseases [Internet]. Bethesda (MD): National Library of Medicine; [cited 2025 Oct 11]. Available from: https://meshb.nlm.nih.gov/record/ui?ui=D002493
9. Raji CA, Ho AJ, Parikshak NN, Becker JT, Lopez OL, Kuller LH, *et al*. Brain structure and obesity. Hum Brain Mapp. 2010;31(3):353-364.
10. McKean-Cowdin R, Barrington-Trimis J, Preston-Martin S. Tumors, central nervous system: epidemiology of. In: Aminoff MJ, Daroff RB, editors. Encyclopedia of the Neurological Sciences. 2nd ed. Amsterdam: Elsevier; c2014, p. 552-560.
11. National Heart, Lung, and Blood Institute. Stroke [Internet]. Hearthealthywomen.org. [cited 2025 Oct 11]. https://www.hearthealthywomen.org/stroke.html
12. Organization of the nervous system [Internet]. Users.rcn.com. [cited 2025 Oct 11]. Available from: https://users.rcn.com/jkimball.ma.ultranet/BiologyPages/N/NervousSystem.html
13. Lipton JO, Sahin M. The neurology of mTOR. Neuron. 2014 Oct;84(2):275-291.